No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
GUTS Fractyl Health
- 5.380
- -0.040-0.74%
Close Jun 18 16:00 ET
- 5.250
- -0.130-2.42%
Post 19:52 ET
257.69MMarket Cap2.45P/E (TTM)
5.460High5.170Low124.29KVolume5.380Open5.420Pre Close658.30KTurnover1.70%Turnover RatioLossP/E (Static)47.90MShares14.50052wk High3.06P/B39.45MFloat Cap5.17052wk Low--Dividend TTM7.33MShs Float14.500Historical High--Div YieldTTM5.35%Amplitude5.170Historical Low5.296Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Is Fractyl Health (NASDAQ:GUTS) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it might be obvious that you need to consider debt, whe
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersVenus Concept (NASDAQ:VERO) stock rose 131.0% to $1.43 during Thursday's after-market session. The market value of their outstanding shares is at $9.0 million. Cyclacel Pharmaceuticals (NASDAQ:
Fractyl Health to Present New Preclinical Obesity Data From Rejuva Platform at the American Diabetes Association's 84th Scientific Sessions
BURLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2
Fractyl Health Presents Compelling Preclinical Data From Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva at Digestive Disease Week 2024
Results showed single-administration GLP-1 pancreatic gene therapy candidate reduced liver weight by 42% (p
Bank of America Securities Reaffirms Their Buy Rating on Fractyl Health, Inc. (GUTS)
Earnings Call Summary | Fractyl Health(GUTS.US) Q1 2024 Earnings Conference
The following is a summary of the Fractyl Health, Inc. (GUTS) Q1 2024 Earnings Call Transcript:Financial Performance:Fractyl Health generated revenue from its commercial pilot in Germany in Q1 2024.Re
Comments
$Fractyl Health(GUTS.US$ Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024. VIA GLOBENEWSWIRE Results showed single-administration GLP-1 pancreatic gene therapy candidate reduced liver weight by 42%
$Fractyl Health(GUTS.US$ Fractyl Health (NASDAQ:GUTS) reported quarterly losses of $(0.17) per share. This is a 97.84 percent increase over losses of $(7.87) per share from the same period last year. The company reported $33.000 thousand in sales this quarter. This is a 560.00 percent increase over sales of $5.000 thousand the same period last year.
1
A Revolutionary Step in Obesity Management: The Approval of Fractyl Health's Revita® Remain-1 Study.
In a groundbreaking development for the field of obesity management, Fractyl Health has received FDA Investigational Device Exemption (IDE) approval for its pivotal Revita® Remain-1 study. This marks a significant milestone in providing durable weight maintenance solutions for patients after the discontinuation of GLP-1 based drugs. With ...
In a groundbreaking development for the field of obesity management, Fractyl Health has received FDA Investigational Device Exemption (IDE) approval for its pivotal Revita® Remain-1 study. This marks a significant milestone in providing durable weight maintenance solutions for patients after the discontinuation of GLP-1 based drugs. With ...
$Fractyl Health(GUTS.US$ No longer looking for reversal! They release FDA news to get the PI! Then they release the big ole earnings loss! Hehehe!
$Fractyl Health(GUTS.US$ Fractyl Health Receives FDA IDE Approval for the Revita Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
Globe Newswire 1-Apr-2024 6:00 AM
Globe Newswire 1-Apr-2024 6:00 AM
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
